Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19268785 | INJECTABLE LEUCOVORIN FORMULATIONS AND METHODS OF PREPARING SAME | July 2025 | January 2026 | Allow | 6 | 1 | 1 | Yes | No |
| 19002144 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | December 2024 | February 2026 | Allow | 14 | 2 | 1 | Yes | No |
| 18948808 | DUAL MODE RADIOTRACER AND-THERAPEUTICS | November 2024 | September 2025 | Allow | 10 | 2 | 0 | No | No |
| 18947606 | RADIOPHARMACEUTICALS | November 2024 | July 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18931596 | RADIOPHARMACEUTICALS INCLUDING ENCAPSULATED GA+99mTc | October 2024 | November 2025 | Allow | 13 | 2 | 1 | No | No |
| 18805445 | CARBONIC ANHYDRASE IX-TARGETING RADIOACTIVE DIAGNOSTIC AND THERAPEUTIC MEDICAMENT AND METHOD FOR PREPARING SAME | August 2024 | October 2025 | Allow | 15 | 3 | 0 | No | No |
| 18791270 | [177LU] LUTETIUM-PSMA I&T COMPOSITION AND DOSIMETRY, KIT, METHOD OF MAKING, AND METHOD OF USING THEREOF | July 2024 | April 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18771562 | Structural Optimization Method to Improve the Theranostic Performance of Peptide Receptor-Targeted Radionuclide Therapy for Cancers | July 2024 | April 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18670587 | RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND | May 2024 | January 2026 | Allow | 19 | 1 | 0 | No | No |
| 18646785 | RADIONUCLIDE LABELED POLYPEPTIDE CONJUGATES AND USES THEREOF | April 2024 | March 2025 | Allow | 11 | 2 | 1 | No | No |
| 18640620 | COMBINATIONS OF IMAGING AGENT CONJUGATES AND APPLICATION THEREOF | April 2024 | March 2026 | Allow | 23 | 3 | 1 | No | No |
| 18640169 | ZWITTERIONIC METAL CHELATORS | April 2024 | June 2025 | Allow | 14 | 2 | 1 | Yes | No |
| 18597037 | METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS | March 2024 | February 2026 | Abandon | 23 | 1 | 0 | No | No |
| 18587915 | NANO-PARTICLES OF MENAQUINONE-9 AND METHODS OF TREATMENT | February 2024 | July 2025 | Allow | 16 | 2 | 0 | Yes | Yes |
| 18432631 | FLUORINE-18 LABELED COMPOSITIONS AND THEIR USE IN IMAGING OF BIOLOGICAL TISSUE | February 2024 | December 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18419562 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | January 2024 | August 2025 | Allow | 18 | 1 | 0 | No | No |
| 18401983 | ELECTROSPUN BIOCOMPATIBLE FIBER COMPOSITIONS | January 2024 | January 2026 | Abandon | 25 | 2 | 0 | No | No |
| 18402399 | HETEROCYCLIC COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | January 2024 | October 2025 | Allow | 21 | 3 | 1 | Yes | No |
| 18390906 | HDAC6 Inhibitors and Imaging Agents | December 2023 | July 2025 | Allow | 19 | 2 | 0 | No | No |
| 18526575 | RADIOLABELLED MGL PET LIGANDS | December 2023 | April 2025 | Allow | 16 | 1 | 0 | No | No |
| 18513283 | MANNOSE DERIVATIVE AND APPLICATION THEREOF | November 2023 | July 2024 | Allow | 8 | 2 | 0 | No | No |
| 18505688 | COMPLEX COMPRISING A PSMA-TARGETING COMPOUND LINKED TO A LEAD OR THORIUM RADIONUCLIDE | November 2023 | March 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18289027 | PEPTIDE LIGAND TARGETING CARBONIC ANHYDRASE IX, PEPTIDE CONSTRUCT COMPRISING SAME, AND USES THEREOF | October 2023 | January 2025 | Allow | 14 | 0 | 1 | No | No |
| 18380822 | METHOD OF USING ADENOSINE AND DIPYRIDAMOLE FOR PHARMACOLOGIC STRESS TESTING, WITH SPECIFIC COMPOSITIONS, UNIT DOSAGE FORMS AND KITS | October 2023 | June 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18477509 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | September 2023 | November 2025 | Allow | 26 | 2 | 0 | Yes | Yes |
| 18477496 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | September 2023 | October 2025 | Allow | 25 | 2 | 0 | Yes | Yes |
| 18456931 | PSMA TARGETED COMPOUNDS AND USES THEREOF | August 2023 | April 2024 | Allow | 7 | 2 | 0 | Yes | No |
| 18452312 | CONJUGATES AND THEIR USE AS IMAGING AGENTS | August 2023 | January 2025 | Allow | 17 | 3 | 0 | Yes | No |
| 18229588 | HETEROARYL COMPOUNDS AND USES THEREOF | August 2023 | September 2025 | Abandon | 26 | 2 | 0 | No | No |
| 18349201 | METHOD FOR PRODUCING Ac-225 SOLUTION AND METHOD FOR PRODUCING MEDICINE USING Ac-225 SOLUTION | July 2023 | April 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18209798 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | June 2023 | September 2025 | Abandon | 28 | 2 | 0 | No | No |
| 18207628 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | June 2023 | March 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18201806 | F-18 LABELED CHIRAL PURE DERIVATIVE OF HYDROXYFURAN, PREPARATION METHOD AND USE THEREOF | May 2023 | August 2024 | Allow | 15 | 3 | 0 | No | No |
| 18200950 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | May 2023 | December 2025 | Allow | 30 | 3 | 0 | No | No |
| 18317224 | ASTATINE SOLUTION AND METHOD FOR PRODUCING SAME | May 2023 | July 2025 | Allow | 26 | 2 | 0 | No | No |
| 18144547 | COMPOUNDS FOR IMAGING TAU PROTEINS THAT ACCUMULATE IN THE BRAIN | May 2023 | September 2024 | Allow | 16 | 1 | 0 | No | No |
| 18310588 | Semifluorocarbon Compound Containing Contrast Agent | May 2023 | February 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18251217 | OLIGONUCLEOTIDE-BASED THERAPEUTICS AND USES THEREOF | April 2023 | July 2025 | Abandon | 27 | 3 | 1 | Yes | No |
| 18305702 | One-Step Labeling of Antibodies to High Specific Activity with Actinium-225 | April 2023 | June 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18135595 | RADIOPHARMACEUTICAL AND METHODS | April 2023 | October 2025 | Allow | 30 | 2 | 0 | Yes | Yes |
| 18149981 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | January 2023 | September 2025 | Abandon | 33 | 3 | 1 | Yes | No |
| 18086075 | CASSETTE FOR STABILISED RADIOLABELLING REACTION | December 2022 | July 2024 | Abandon | 19 | 2 | 0 | No | No |
| 18061715 | RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS | December 2022 | July 2024 | Abandon | 19 | 2 | 0 | No | No |
| 17962686 | ELUENT SOLUTION | October 2022 | June 2025 | Abandon | 32 | 2 | 0 | Yes | No |
| 17956326 | F-18 POSITRON DIAGNOSTIC CONTRAST AGENT PRECURSOR AND METHOD OF MANUFACTURING THE SAME | September 2022 | September 2025 | Allow | 36 | 0 | 1 | No | No |
| 17882708 | PHARMACEUTICAL COMPOSITION CONTAINING 211AT-LABELED AMINO ACID DERIVATIVE, AND METHOD FOR PRODUCING SAID PHARMACEUTICAL COMPOSITION | August 2022 | November 2025 | Abandon | 39 | 4 | 0 | Yes | No |
| 17879351 | MULTIMODAL PET/MRI CONTRAST AGENT AND A PROCESS FOR THE SYNTHESIS THEREOF | August 2022 | April 2025 | Abandon | 32 | 2 | 0 | No | No |
| 17795792 | STRUCTURAL OPTIMIZATION METHOD TO IMPROVE THE THERANOSTIC PERFORMANCE OF PEPTIDE RECEPTOR-TARGETED RADIONUCLIDE THERAPY FOR CANCERS | July 2022 | August 2025 | Allow | 37 | 2 | 0 | No | No |
| 17759336 | METHOD FOR THE PREPARATION OF N-MONOFLUOROALKYL TROPANES AND THEIR USE | July 2022 | October 2025 | Allow | 39 | 1 | 0 | No | No |
| 17870973 | Method, Apparatus, and System for Radiation Therapy | July 2022 | September 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17869104 | METHOD FOR PRODUCING Ac-225 SOLUTION AND METHOD FOR PRODUCING MEDICINE USING Ac-225 SOLUTION | July 2022 | May 2023 | Allow | 10 | 2 | 0 | No | No |
| 17793091 | FATTY ACID DERIVATIVE LABELED WITH POSITRON-EMITTING RADIONUCLIDE | July 2022 | January 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17810370 | FAP INHIBITOR | July 2022 | January 2025 | Abandon | 30 | 3 | 0 | No | No |
| 17854532 | 177-LU LABELED ACTIVE SITE INHIBITED FACTOR VII | June 2022 | November 2025 | Allow | 40 | 2 | 0 | Yes | Yes |
| 17850056 | RADIOPHARMACEUTICAL PRODUCTS | June 2022 | June 2025 | Abandon | 35 | 2 | 0 | No | No |
| 17849297 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | June 2022 | April 2025 | Allow | 34 | 4 | 0 | No | Yes |
| 17846690 | METHODS OF CANCER DETECTION USING PARPI-FL | June 2022 | January 2026 | Abandon | 43 | 4 | 0 | No | No |
| 17836994 | Metal Tricarbonyl Complexes Comprising Substituted Iminodiactic Acid Ligands and Uses as Radioisotope Tracers | June 2022 | January 2025 | Abandon | 31 | 2 | 0 | No | No |
| 17757017 | RADIOMICS-BASED TREATMENT DECISION SUPPORT FOR LUNG CANCER | June 2022 | June 2025 | Allow | 37 | 1 | 0 | No | No |
| 17831698 | RADIOPHARMACEUTICAL COMPOSITIONS OF RADIOACTIVE HALOGENATED BENZYLGUANIDINE | June 2022 | February 2025 | Abandon | 33 | 4 | 0 | No | No |
| 17745100 | LABELING PRECURSORS WITH SQUARIC ACID COUPLING | May 2022 | June 2023 | Allow | 13 | 1 | 1 | No | No |
| 17776330 | RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES | May 2022 | January 2026 | Allow | 44 | 1 | 1 | No | No |
| 17775150 | RADIOLABELLED TARGETING LIGANDS | May 2022 | November 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17729881 | DEUTERATED COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | April 2022 | December 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17722628 | RADIOLIGANDS FOR IMAGING THE ID01 ENZYME | April 2022 | May 2025 | Abandon | 37 | 2 | 0 | No | Yes |
| 17715661 | ISOINDOLINONE COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | April 2022 | February 2026 | Allow | 46 | 2 | 0 | No | No |
| 17695252 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | March 2022 | May 2024 | Abandon | 26 | 2 | 0 | No | No |
| 17642179 | PSMA BINDER AND USE THEREOF | March 2022 | June 2025 | Allow | 40 | 4 | 0 | No | No |
| 17592684 | SYSTEM AND METHOD FOR QUANTITATIVE MAPPING OF MITOCHONDRIAL COMPLEX 1 | February 2022 | January 2024 | Abandon | 23 | 2 | 0 | No | No |
| 17649930 | METHOD AND DEVICE FOR DIRECT PRODUCTION OF RADIO-ISOTOPE BASED CANCER TREATMENT PHARMACEUTICALS | February 2022 | May 2024 | Allow | 27 | 3 | 0 | Yes | No |
| 17574838 | ELECTROSPUN BIOCOMPATIBLE FIBER COMPOSITIONS | January 2022 | May 2024 | Abandon | 28 | 2 | 0 | No | No |
| 17557755 | ELUENT SOLUTION | December 2021 | June 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17619791 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | December 2021 | January 2026 | Allow | 49 | 2 | 1 | Yes | Yes |
| 17534711 | Imaging Agents | November 2021 | June 2024 | Abandon | 31 | 2 | 0 | Yes | No |
| 17455170 | HDAC6 Inhibitors and Imaging Agents | November 2021 | September 2023 | Allow | 22 | 1 | 0 | No | No |
| 17522144 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | November 2021 | December 2023 | Abandon | 25 | 2 | 1 | No | No |
| 17594325 | CONJUGATES AND THEIR USE AS IMAGING AGENTS | October 2021 | October 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17486875 | RADIOPHARMACEUTICAL AND METHODS | September 2021 | May 2023 | Abandon | 20 | 3 | 0 | Yes | No |
| 17477479 | NOVEL COMPOUNDS FOR IMAGING TAU PROTEINS THAT ACCUMULATE IN BRAIN | September 2021 | February 2023 | Allow | 17 | 2 | 1 | Yes | No |
| 17477411 | HETEROARYL COMPOUNDS AND USES THEREOF | September 2021 | October 2023 | Abandon | 25 | 4 | 1 | Yes | No |
| 17439536 | RIGIDIFIED PENTADENTATE CHELATING AGENTS USEFUL FOR THE [AL18F]2+ LABELLING OF BIOMOLECULES | September 2021 | April 2025 | Allow | 43 | 2 | 0 | No | No |
| 17474916 | COMPLEX POLYSACCHARIDE-BOUND RADIOISOTOPE CHELATES AND METHODS OF TREATING MALIGNANCIES THEREWITH | September 2021 | June 2022 | Abandon | 9 | 1 | 0 | No | No |
| 17436162 | [18F]-Labeled Benzothiazole Derivative As PET Radiotracer | September 2021 | June 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17433309 | USE OF ECHOGENIC COATING FOR ULTRASOUND IMAGING OF MEDICAL DEVICES IN DEEP TISSUE LAYERS | August 2021 | March 2026 | Abandon | 54 | 4 | 0 | Yes | No |
| 17310758 | COMBINATION OF PD-1/PD-L1 INHIBITORS AND TARGETED THORIUM CONJUGATES | August 2021 | January 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17395319 | METAL COMPLEXES AND FLUORINATION THEREOF | August 2021 | May 2025 | Abandon | 45 | 4 | 0 | No | No |
| 17395055 | HETEROBIARYL COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | August 2021 | March 2024 | Allow | 31 | 3 | 1 | Yes | No |
| 17390284 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | July 2021 | March 2026 | Allow | 56 | 4 | 0 | No | Yes |
| 17372410 | RADIOLABELLED AND NONRADIOLABELLED PEGYLATED COMPOUNDS AND USES THEREOF | July 2021 | February 2024 | Abandon | 32 | 2 | 0 | No | No |
| 17366681 | NOVEL FORMULATION AND METHOD OF SYNTHESIS | July 2021 | April 2024 | Abandon | 34 | 2 | 0 | No | No |
| 17356757 | PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND | June 2021 | February 2024 | Abandon | 32 | 2 | 0 | No | No |
| 17353611 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | June 2021 | March 2024 | Allow | 32 | 3 | 1 | Yes | No |
| 17353627 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | June 2021 | August 2023 | Allow | 26 | 2 | 1 | No | No |
| 17344739 | COMPOSITIONS AND METHODS FOR MEASURING OXIDATIVE STRESS | June 2021 | October 2025 | Allow | 53 | 6 | 0 | Yes | No |
| 17344582 | HETEROCYCLIC COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | June 2021 | September 2023 | Allow | 28 | 3 | 1 | Yes | No |
| 17317133 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | May 2021 | January 2025 | Allow | 45 | 3 | 0 | No | Yes |
| 17317529 | COMPOSITION AND METHODS FOR TUMOR IMAGING AND TREATMENT | May 2021 | July 2024 | Allow | 38 | 2 | 0 | Yes | Yes |
| 17314158 | PURIFICATION METHOD AND COMPOSITIONS | May 2021 | February 2025 | Abandon | 45 | 4 | 0 | Yes | No |
| 17314366 | METHODS AND MATERIALS FOR MAKING PET RADIOTRACERS | May 2021 | November 2025 | Abandon | 54 | 2 | 0 | No | Yes |
| 17246184 | TAU PET IMAGING LIGANDS | April 2021 | September 2023 | Abandon | 28 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DONOHUE, SEAN R.
With a 43.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DONOHUE, SEAN R works in Art Unit 1618 and has examined 678 patent applications in our dataset. With an allowance rate of 40.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner DONOHUE, SEAN R's allowance rate of 40.4% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DONOHUE, SEAN R receive 2.67 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by DONOHUE, SEAN R is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +20.6% benefit to allowance rate for applications examined by DONOHUE, SEAN R. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 11.9% of applications are subsequently allowed. This success rate is in the 7% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 27.0% of cases where such amendments are filed. This entry rate is in the 38% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 27.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 30% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 53.5% of appeals filed. This is in the 24% percentile among all examiners. Of these withdrawals, 41.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 85.8% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 51% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.